VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.42	0.48	0.93	20.99	0.44
Revenue Growth (YoY)	-11.11%	-48.76%	-95.57%	4638.83%	-87.68%
Cost of Revenue	0	0	0	1.39	0
Gross Profit	0.42	0.48	0.93	19.6	0.44
Selling, General & Admin	13.38	16.39	20.3	89.54	45.11
Research & Development	16.31	18.39	19.54	43.53	51.2
Other Operating Expenses	0	0	0	139.07	0
Operating Expenses	29.68	34.77	39.84	272.15	96.32
Operating Income	-29.26	-34.3	-38.91	-252.55	-95.87
Interest Expense / Income	0	0	5.61	4.39	0.92
Other Expense / Income	-0.81	-11.1	29.26	-1.11	-1.44
Pretax Income	-28.45	-23.2	-73.78	-255.83	-95.35
Income Tax	0	0.01	-0.45	-0.26	-0.18
Net Income	-28.45	-23.21	-73.33	-255.57	-95.18
Shares Outstanding (Basic)	10	3	3	2	0
Shares Outstanding (Diluted)	10	3	3	2	0
Shares Change	222.44%	11.44%	58.75%	282.06%	31.22%
EPS (Basic)	-2.78	-7.28	-25.64	-141.84	-201.96
EPS (Diluted)	-2.78	-7.28	-25.64	-141.84	-201.96
Free Cash Flow	-25.34	-29.2	-56.37	-137.2	-74.41
Free Cash Flow Per Share	-2.47	-9.16	-19.72	-76.18	-157.86
Gross Margin	100.00%	100.00%	100.00%	93.37%	100.00%
Operating Margin	-6900.47%	-7189.73%	-4179.48%	-1203.00%	-21641.76%
Profit Margin	-6710.38%	-4865.83%	-7876.37%	-1217.40%	-21484.88%
Free Cash Flow Margin	-5976.65%	-6121.59%	-6054.46%	-653.53%	-16797.29%
EBITDA	-28.45	-23.13	-68.06	-251.1	-94.08
EBITDA Margin	-6710.38%	-4848.01%	-7310.20%	-1196.09%	-21237.70%
Depreciation & Amortization	0	0.07	0.11	0.34	0.35
EBIT	-28.45	-23.2	-68.17	-251.44	-94.43
EBIT Margin	-6710.38%	-4863.10%	-7321.91%	-1197.71%	-21316.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).